MacroGenics Announces Date of Third Quarter 2022 Financial Results Conference Call
October 26, 2022 16:30 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Oct. 26, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics to Participate in Upcoming Investor Conferences
September 02, 2022 07:00 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Sept. 02, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics...
MacroGenics Provides Update on Corporate Progress and Second Quarter 2022 Financial Results
August 08, 2022 16:01 ET
|
MacroGenics, Inc.
First patient dosed in Phase 1 study of MGD024 in CD123-positive hematologic malignanciesPlan to initiate MGC018 Phase 2/3 study in prostate cancer by year-endInitiates cost-saving measures through...
MacroGenics Announces Date of Second Quarter 2022 Financial Results Conference Call
July 25, 2022 16:01 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, July 25, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics Announces Closure of CP-MGA271-06 Study Evaluating Enoblituzumab plus Checkpoint Inhibition in Head and Neck Cancer
July 08, 2022 16:30 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, July 08, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the...
MacroGenics to Participate in Upcoming Investor Conference
June 08, 2022 16:01 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, June 08, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for...
MacroGenics Announces Appointment of William Heiden to Board of Directors
May 23, 2022 16:01 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, May 23, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the...
MacroGenics to Participate in Upcoming Investor Conference
May 17, 2022 16:01 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, May 17, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the...
MacroGenics Provides Update on Corporate Progress and First Quarter 2022 Financial Results
May 03, 2022 16:01 ET
|
MacroGenics, Inc.
Plan to start Phase 2/3 prostate cancer study with MGC018 by year-end Initiated Phase 1 study of MGC018 in combination with lorigerlimab in advanced solid tumorsTargeting mid-2022 start of Phase 1...
MacroGenics Announces Date of First Quarter 2022 Financial Results Conference Call
April 25, 2022 16:12 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, April 25, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...